



New-to-Market Medical Pharmacy Products Currently Under Clinical Review by Medica

Updated 8/31/2021

Brand name	Generic name	J code	National Drug Codes (NDCs)	Date of FDA approval
Aduhelm	aducanumab-avwa	J3590	64406-101-01, 64406-102-02	June 7, 2021
Camcevi	leuprolide mesylate	J9999	NA	May 25, 2021
Nexviazyme	avalglucosidase alfa-ngpt	J3590	58468-0426-1	August 6, 2021
Ryplazim	plasminogen human-tvmh	J3590	70573-099-01	June 4, 2021
Saphanelo	anifrolumab-fnia	J3590	00310-3040-00	July 30, 2021

Note: Drugs recently removed from this list have been addressed under new [Medica drug management policies](#).

This list is provided for our provider network's convenience and information. While this list is intended to be comprehensive, the U.S. Food and Drug Administration (FDA) approval process and its timing are outside of Medica's control. Medica reserves the right to adjust claims for any new-to-market medical pharmacy products as discussed in [the New-to-Market Medical Pharmacy Products coverage policy](#).